BioSpace News Archive

DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potential

Supply also expected to benefit from shift to lower-dose product mix, including potential variant booster vaccines and pediatric primary vaccine doses

Hutchison China MediTech Limited has initiated a registration-intent Phase II clinical trial of HMPL-689, its highly selective and potent PI3Kδ inhibitor, in China in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma, two subtypes non-Hodgkin’s lymphoma.

Amarin Corporation plc, announced that Joseph T. Kennedy has informed the board of directors of his decision to retire as executive vice president, general counsel and strategic initiatives.

Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its first quarter of 2021 ended March 31, 2021, after the market closes on Thursday, May 6th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021 . First Quarter 2021 Highlights First quarter revenue increased 59% to $9.91 billion . First quarter GAAP diluted earnings per share (EPS) increased 198% to $5.

RepliCel Life Sciences Inc., a company developing next-generation technologies in aesthetics and orthopedics, announced it has closed the second tranche of the investment by MainPointe Pharmaceuticals as outlined in the share purchase agreement signed earlier this year by the parties.

Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2021 financial results and provide a business update on Thursday, May 6, 2021 at 7:30 a.m. ET.

Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes Expenses Managed in Q1 2021 to Minimize Operating Loss Despite Revenue Impact of COVID-19 and Other Factors